support@mellalta.com   +1 (304) 306-0723

KRAS inhibitors-Market opportunity, Epidemiology & Market Forecast, Pipeline and Competitive Analysis, 2020-2030

$3,250.00$9,750.00

This KRAS report covers the KRAS market opportunity providing key competitive analysis, 37 companies with pipeline drug profiles, clinical trials, upcoming events, other Developments (Collaborations Details, Funding, etc.), Epidemiology forecast of Cancers with KRAS mutation and % of mutation frequency, licensing and deals, as well as presenting market forecast from 2019 to 2030.

Clear

Description

Kirsten rat sarcoma viral oncogene homolog (KRAS) mutation may directly influence medical decisions in patients with carcinomas as demonstrated by the recent research. Despite its discovery over three decades ago, it’s remained elusive as a drug target, although several downstream mediators are effectively drugged. KRAS itself is described collectively of the master switches for cancer and is especially associated as a driver for Colorectal Carcinoma (CRC), Non-small Lung cancer (NSCLC), and carcinoma.

While KRAS mutations are present in up to 25% of cancers, the oncogenic variants have different prevalence rates in numerous cancers. As per the American Cancer Society, around 200,000 patients are diagnosed every year with lung adenocarcinomas. That puts the KRAS-G12C population within the USA at 14,000–28,000 patients annually. within the case of KRAS-G12C-positive colorectal cancer (CRC), closer to 3000 patients are diagnosed every year.

Amgen certainly has a headstart over its potential opponents, and it is unlikely that a competitor would have the option to sling in front of an expedited development program for AMG 510. Mirati Therapeutics, another competitor, entered the clinic with the KRAS-G12C inhibitor MRTX849, followed by other companies. While there is already a lot of excitement about the new drug, the number of patients who have been treated with it is relatively small.

This KRAS report covers the KRAS market opportunity providing key competitive analysis, 37 companies with pipeline drug profiles, clinical trials, upcoming events, other Developments (Collaborations Details, Funding, etc.), Epidemiology forecast of Cancers with KRAS mutation and % of mutation frequency, licensing and deals, as well as presenting market forecast from 2019 to 2030.

Key Takeaways from the Report

  • Indication Prioritization: KRAS Mutation patterns in cancers
  • KRAS Mutated Cancers Epidemiology Forecast from 2019-2030
  • Business Transactions & Strategies: Key collaborations and deal values
  • Pipeline Development: Product Profiles, Clinical Trials & Results
  • Market Forecast of KRAS Inhibitors from 2019-2030
  • Recent & Upcoming events

Table of Contents

  1. OVERVIEW
  2. KEY TAKEAWAYS
  3. The KRAS Target BACKGROUND
  4. Indication Prioritization
    • KRAS Mutation patterns in cancers
  5. KRAS CANCERS EPIDEMIOLOGY
    • Incidence for KRAS Mutated Cancers in the US and EU
    • Frequency of KRAS G12C & KRAS G12D by Tumour Type
  6. KRAS LICENSING AND COLLABORATION DEALS
    • KRAS Licensing Details and Deal values
    • KRAS Acquisition Details & Deal Values
  7. KRAS PIPELINE LANDSCAPE
    • KRAS Pipeline Analysis
    • KRAS Clinical Trial Landscape
  8. KRAS PIPELINE DRUG PROFILES & CLINICAL TRIAL ANALYSIS
    • Amgen: AMG 510
      • Product Profile & Description
      • Clinical Trials
      • Collaborations
      • Other Developments
    • Mirati: MRTX 849
      • Product Profile & Description
      • Clinical Trials
      • Collaborations
      • Other Developments
    • Boehringer Ingelheim: BI 1701963
      • Product Profile & Description
      • Clinical Trials
      • Collaborations
      • Other Developments
    • List of drugs continued….
  9. Market Forecast
    • Amgen 510 Sales Potential
    • Revenue Opportunity
  10. KOL VIEWS ON KRAS
  11. UPCOMING EVENTS
  12. Appendix

List of Tables

  1. KRAS Oncogenic mutations frequency in human cancers, 2020
  2. Global Incidence cases of KRAS mutated Cancers Overview, 2020
  3. Incidence cases of NSCLC adenocarcinoma & Frequency of KRAS G12C & KRAS G12D, 2020-2030
  4. Incidence cases of Colorectal adenocarcinoma & Frequency of KRAS G12C & KRAS G12D, 2020-2030
  5. Incidence cases of Pancreatic adenocarcinoma, & Frequency of KRAS G12C & KRAS G12D, 2020-2030
  6. Incidence cases of Endometrial adenocarcinoma, & Frequency of KRAS G12C & KRAS G12D, 2020-2030
  7. KRAS Licensing Details and Deal values, 2020
  8. KRAS Acquisition Details & Deal Values, 2020
  9. Total Products for KRAS Inhibitors by Phase, 2020
  10. Total Products for KRAS Inhibitors in Clinical Trials, 2020
  11. Amgen 510 Sales Potential by Cancers, 2020-2030
  12. Revenue Potential for KRAS inhibitors
  13. Upcoming Events for KRAS, 2020

List of Figures

  1. The KRAS cycle
  2. KRAS Oncogenic mutations frequency in human cancers, 2020
  3. Global Incidence cases of KRAS mutated Cancers Overview, 2020
  4. Incidence cases of NSCLC adenocarcinoma & Frequency of KRAS G12C & KRAS G12D, 2020-2030
  5. Incidence cases of Colorectal adenocarcinoma & Frequency of KRAS G12C & KRAS G12D, 2020-2030
  6. Incidence cases of Pancreatic adenocarcinoma, & Frequency of KRAS G12C & KRAS G12D, 2020-2030
  7. Incidence cases of Endometrial adenocarcinoma, & Frequency of KRAS G12C & KRAS G12D, 2020-2030
  8. KRAS Licensing Details and Deal values, 2020
  9. KRAS Acquisition Details & Deal Values, 2020
  10. Total Products for KRAS Inhibitors by Phase, 2020
  11. Total Products for KRAS Inhibitors in Clinical Trials, 2020
  12. Amgen 510 Sales Potential by Cancers, 2020-2030
  13. Revenue Potential for KRAS inhibitors
  14. Upcoming Events for KRAS, 2020

Companies Covered

  1. Silenseed
  2. Amgen
  3. Gilead
  4. Mirati Therapeutics
  5. Johnson & Johnson
  6. Merck, Moderna Therapeutics
  7. Oblique Therapeutics
  8. Johnson & Johnson
  9. Aurigene
  10. Cotinga Pharmaceuticals
  11. Codiak Biosciences
  12. Mirati Therapeutics
  13. Revolution Medicines
  14. Boehringer Ingelheim
  15. Bayer
  16. Sanofi/X-Chem
  17. X-Chem
  18. BridgeBio Pharma
  19. Others
Name
Email
Phone
Enquiry

Get In Touch

Let's keep the conversation going